FDA accepts Global Blood’s application for voxelotor for sickle cell disease

Global Blood Therapeutics (NASDAQ:GBT) is up 14% premarket on light volume in reaction to the FDA’s acceptance of its marketing application seeking approval of voxelotor for the treatment of sickle cell disease (SCD).

The agency’s action date under Priority Review status is February 26, 2020.

https://seekingalpha.com/news/3497272-fda-accepts-global-bloods-application-voxelotor-scd-shares-14-percent-premarket